Engineering Scalable Manufacturing of High-Quality Stem Cell-Derived Cardiomyocytes for Cardiac Tissue Repair
Year: 2018
Type: review
Abstract: Recent advances in the differentiation and production of human pluripotent stem cell (hPSC)-derived cardiomyocytes (CMs) have stimulated development of strategies to use these cells in human cardiac regenerative therapies. A prerequisite for clinical trials and translational implementation of hPSC-derived CMs is the ability to manufacture safe and potent cells on the scale needed to replace cells lost during heart disease. Current differentiation protocols generate fetal-like CMs that exhibit proarrhythmogenic potential. Sufficient maturation of these hPSC-derived CMs has yet to be achieved to allow these cells to be used as a regenerative medicine therapy. Insights into the native cardiac environment during heart development may enable engineering of strategies that guide hPSC-derived CMs to mature. Specifically, considerations must be made in regard to developing methods to incorporate the native intercellular interactions and biomechanical cues into hPSC-derived CM production that are conducive to scale-up.
Source: Frontiers in Medicine
Authors: Kaitlin K. Dunn, Sean P. Palecek
Institution: University of Wisconsin–Madison
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: EAGER: Biomanufacturing: Engineering Cell-Intrinsic Control of Cardiomyocyte Differentiation in Human Pluripotent Stem Cells, Integrated Manufacturing of Therapeutic Cardiac Cells, NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), Chemistry-Biology Interface Training Program, Paracrine interactions during cardiac and endothelial co-differentiation of hPSCs
OpenAlex ID: W2799794650